AU
UK
CA
NZ
IND
US
AbCellera Biologics Inc. (Nasdaq: ABCL) has received a No Objection Letter (NOL) from Health Canada, authorizing the company to proceed with a Phase 1 clinical trial for its investigational drug candidate ABCL635. The study is focused on addressing moderate-to-severe vasomotor symptoms (VMS), commonly referred …
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company focused on treating Obstructive Sleep Apnea (OSA), announced its financial results for the first quarter of 2025, reporting revenue of €1.1 million, down from €1.2 million in the same quarter last year.
Highlights
argenx SE [Euronext & Nasdaq: ARGX], a biotechnology firm focused on autoimmune diseases, announced its financial results for the first quarter of 2025, alongside updates on its expanding pipeline and regulatory progress. The company reported $790 million in global net product sales from VYVGART® …
Evotec SE (NASDAQ: EVO) has reported its financial results for Q1 2025, showcasing a solid start to the year despite challenges in the drug discovery market. The company achieved revenues of €200 million, a 4% decline compared to Q1 2024, aligning with their expectations. …
BriaCell Therapeutics Corp., a clinical-stage biotechnology company, has presented new data from its ongoing pivotal Phase 3 trial of Bria-IMT™, an investigational immunotherapy for metastatic breast cancer (MBC). The study, titled BRIA-ABC (NCT06072612), explores how specific biomarkers might predict patient response to the Bria-IMT …
Basel Medical Group Ltd (Nasdaq: BMGL) has completed the acquisition of Bethesda Medical Pte. Ltd., a Singapore-based healthcare provider with three decades of experience in diagnostic imaging and outpatient medical services. The move strengthens Basel Medical’s footprint in Singapore and initiates its broader strategy …
The European Commission has approved the conversion of the conditional marketing approval (CMA) for FILSPARI into a standard marketing authorization (MA) for the treatment of primary IgA nephropathy (IgAN) in adults with a urine protein excretion of ≥1.0 g/day. This authorization applies across all …
Highlights
Please wait processing your request...